Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)

Phase 4 Withdrawn University of British Columbia Provincial Health Services Authority British Columbia · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of schizophrenia.

Timeline

Start: 2008-04
Primary completion: 2012-05
Completion: 2012-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	1 mg	—

Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)

Summary

Timeline

Drugs

Indications